Table 1 Univariable and multivariable analyses based on clinical information for astrocytoma and oligodendroglioma

TCGA (n = 140) (n/%)

TCGA (n = 94) (n/%)

Age (y)

0.635

Age (y)

 < 50 (reference, 119/85%)

1

1

 < 50 (reference, 66/70.2%)

1

1

 50–59 (14/10%)

0.001 (0–Inf)

0.517

0.001 (0–Inf)

 50–59 (17/18.1%)

2.66 × 10⁹ (0–Inf)

1

3.37 × 10⁹ (0–Inf)

1

 > 60 (7/5%)

0.85 (0.20–3.63)

0.72 (0.16–3.26)

 > 60 (11/11.7%)

7.72 × 10^–9 (0–Inf)

0.999

5.72 × 10^–9 (0–Inf)

0.999

Gender

Gender

 Female (reference, 67/47.9%)

1

1

 Female (reference, 43/45.7%)

1

1

 Male (73/52.1%)

1.03 (0.48–2.20)

0.509

1.15 (0.51–2.62)

 Male (51/54.3%)

0.24 (0.03–2.14)

0.203

0.46 (0.03–7.99)

0.593

Radiotherapy

Radiotherapy

 No (reference, 69/49.3%)

1

1

 No (reference, 68/72.3%)

1

1

 Yes (71/50.7%)

1.20 (0.55–2.66)

0.519

1.22 (0.49–3.05)

 Yes (27/28.7%)

0.46 (0.04–4.88)

0.521

0.26 (0.02–3.11)

0.29

Chemotherapy

Chemotherapy

 No (reference, 87/62.1%)

1

1

 No (reference, 60/63.8%)

1

1

 Yes (53/37.9%)

1.20 (0.54–2.71)

0.587

1.17 (0.47–2.93)

 Yes (34/36.2%)

1.4 (0.23–8.54)

0.713

1.51 (0.22–10.20)

0.67

MGMT

MGMT

 Unmethylated (reference, 16/11.4%)

1

1

 Unmethylated (reference, 1/1.1%)

1

1

 Methylated (124/88.6%)

0.43 (0.10–1.83)

0.541

0.38 (0.08–1.71)

 Methylated (93/98.9%)

0.3 × 10^–6 (0–Inf)

0.999

0.36 (0–Inf)

1

ATRX

TERT

 MT (reference, 108/77.1%)

1

1

 MT (reference, 49/52.1%)

1

1

 WT (32/22.9%)

0.97 (0.39–2.43)

0.473

0.88 (0.33–2.31)

 WT (2/2.1%)

0.31 (0.04–2.67)

0.284

0.52 (0.02–11.03)

0.675

DNA methylation

 Unclear (43/45.7%)

2.34 × 10^–8 (0-Inf)

0.999

1.3 × 10^–9 (0–Inf)

1

 G-CIMP-high (reference, 137/97.9%)

1

1

 Codel (3/2.1%)

9.17 × 10⁴ (0–Inf)

0.506

2.63 × 10⁵ (0–Inf)

CGGA cohort 1 (n = 80) (n/%)

PRS

CGGA Cohort 1 (n = 100) (n/%)

 Primary (reference, 71/88.8%)

1

1

PRS

0.672

 Recurrent (9/11.3%)

20.05 (6.10–65.91)

 < 0.001

19.64 (4.09–94.27)

 < 0.001

 Primary (reference, 81/81.0%)

1

1

Age (y)

 Recurrent (19/19%)

1.95 (0.97–3.92)

0.606

3.08 (1.44–6.59)

  < 50 (reference, 70/87.5%)

1

1

Age (y)

 50–59 (8/10%)

9.59 (1.14–80.40)

0.037

6.88 (0.53–88.75)

0.139

 < 50 (reference, 88/88%)

1

1

 > 60 (2/2.5%)

2.83 (0.79–10.12)

0.11

0.64 (0.12–3.34)

0.56

 50–59 (11/11%)

2.69 (0.36–19.87)

0.556

1.75 (0.22–13.75)

Gender

 > 60 (1/1%)

1.93 (0.81–4.62)

2.4 (0.98–5.89)

 Female (reference, 34/42.5%)

1

1

Gender

 Male (46/57.5%)

0.97 (0.37–2.55)

0.951

1.09 (0.38–3.13)

0.868

 Female (reference, 37/37%)

1

1

Radiotherapy

 Male (64/64%)

0.59 (0.32–1.09)

0.538

0.49 (0.26–0.95)

 No (reference, 13/16.3%)

1

1

Radiotherapy

 Yes (67/83.7%)

0.70 (0.16–3.18)

0.647

0.53 (0.11–2.60)

0.434

 No (reference, 18/18%)

1

1

Chemotherapy

 Yes (82/82%)

1.86 (0.73–4.75)

0.551

2.18 (0.81–5.85)

 No (reference, 50/62.5%)

1

1

Chemotherapy

 Yes (30/37.5%)

3.46 (1.29–9.29)

0.014

2.2 (0.74–6.53)

0.155

 No (reference, 54/54%)

1

 Yes (46/46%)

1.52 (0.82–2.81)

0.545

1